Allianz Asset Management GmbH Decreases Stock Position in Biogen Inc. $BIIB

Allianz Asset Management GmbH lessened its holdings in Biogen Inc. (NASDAQ:BIIB) by 24.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 396,803 shares of the biotechnology company’s stock after selling 130,257 shares during the quarter. Allianz Asset Management GmbH’s holdings in Biogen were worth $55,584,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Empowered Funds LLC boosted its stake in Biogen by 64.9% in the 1st quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock worth $965,000 after purchasing an additional 2,777 shares in the last quarter. Focus Partners Wealth raised its holdings in shares of Biogen by 172.2% in the first quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock worth $1,392,000 after buying an additional 6,436 shares during the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of Biogen during the second quarter worth $216,000. Janney Montgomery Scott LLC lifted its stake in shares of Biogen by 6.5% during the second quarter. Janney Montgomery Scott LLC now owns 19,099 shares of the biotechnology company’s stock worth $2,399,000 after buying an additional 1,158 shares during the period. Finally, Ameritas Advisory Services LLC purchased a new stake in shares of Biogen during the second quarter valued at $76,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on BIIB. Truist Financial raised their target price on Biogen from $142.00 to $190.00 and gave the stock a “hold” rating in a research note on Thursday, January 8th. Oppenheimer raised their price objective on Biogen from $205.00 to $225.00 and gave the stock an “outperform” rating in a research note on Friday, January 30th. Morgan Stanley lifted their target price on Biogen from $149.00 to $156.00 and gave the stock an “equal weight” rating in a report on Friday, December 12th. Stifel Nicolaus upgraded shares of Biogen from a “hold” rating to a “buy” rating and increased their price target for the stock from $144.00 to $202.00 in a report on Thursday, November 6th. Finally, Guggenheim lifted their price objective on shares of Biogen from $165.00 to $185.00 in a research note on Friday, October 31st. Eleven equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $192.58.

Insiders Place Their Bets

In other Biogen news, insider Priya Singhal sold 748 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $179.30, for a total value of $134,116.40. Following the completion of the transaction, the insider owned 6,271 shares in the company, valued at approximately $1,124,390.30. This represents a 10.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.18% of the company’s stock.

Biogen Stock Performance

BIIB opened at $185.45 on Thursday. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.72 and a quick ratio of 2.04. The firm has a fifty day moving average price of $176.48 and a 200 day moving average price of $155.92. Biogen Inc. has a 1 year low of $110.04 and a 1 year high of $190.20. The stock has a market cap of $27.21 billion, a P/E ratio of 16.91, a P/E/G ratio of 1.48 and a beta of 0.16.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Nature Medicine published pivotal DEVOTE results showing the high‑dose nusinersen regimen produced statistically significant motor and biomarker improvements versus lower dose / untreated comparators; safety was broadly consistent and the regimen is under FDA review with an April 3 PDUFA date — a clear potential revenue and label expansion catalyst for SPINRAZA. Nature Medicine Publishes DEVOTE Results
• Positive Sentiment: RBC Capital issued a buy/outperform view on BIIB, which supports upward price momentum by increasing institutional confidence and may attract more buyers ahead of earnings and the PDUFA decision. Biogen Receives a Buy from RBC Capital
• Neutral Sentiment: Market previews flag Q4 results and guidance as near‑term drivers — MS franchise pressures are a headwind but growth from newer assets (Leqembi, Skyclarys) could help offset declines; earnings delivery will likely drive short‑term volatility. Biogen Reports Q4: Everything You Need To Know Ahead Of Earnings
• Neutral Sentiment: Zacks preview notes new drug dynamics are key heading into Q4 — useful context but not an immediate directional trigger absent surprises in the print or guidance. New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings
• Neutral Sentiment: Bernstein maintained a Hold (market‑perform) with a ~$191 target, signaling mixed near‑term fundamentals but acknowledging optional upside from emerging assets — this keeps analyst sentiment balanced. Biogen: Unexciting Near-Term Fundamentals but Optionality in Emerging Assets
• Negative Sentiment: An insider (Priya Singhal) disclosed a sale of 748 shares (~$134k) on Feb 2; small in size but sometimes viewed as a modest negative signal by some investors. Insider Form 4 — Priya Singhal Sale

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.